1201 - 1210 of 7939 Results
Title
Year
-
RESTRICTEDTitle: Somatic CNV Detection by Single-Cell Whole-Genome Sequencing in Postmortem Human BrainJournal Name: Methods in Molecular BiologyPublisher: Springer USVol:Issue #:Start Page: 205End Page: 230Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/978-1-0716-2655-9_11Citation Count: 3
- Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy2022RESTRICTEDTitle: Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment StrategyJournal Name: International Journal of Molecular SciencesPublisher: MDPI AGVol: 23Issue #: 22Start Page: 14340End Page: 14340Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3390/ijms232214340Best OA location URL: https://www.mdpi.com/1422-0067/23/22/14340/pdf?version=1669106553Citation Count: 8
- BDNF rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's disease2022OPENTitle: BDNF rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's diseaseJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.1053591Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.1053591/pdfCitation Count: 0
- Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome2022OPENTitle: Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisomeJournal Name: Alzheimer's Research & TherapyPublisher: Springer Science and Business Media LLCVol: 14Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s13195-022-01113-5Best OA location URL: https://alzres.biomedcentral.com/counter/pdf/10.1186/s13195-022-01113-5Citation Count: 65
- Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline2022OPENTitle: Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive declineJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 106Issue #:Start Page: 105221End Page: 105221Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.11.013Best OA location URL: http://www.prd-journal.com/article/S1353802022003819/pdfCitation Count: 3
-
RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 9
-
RESTRICTEDTitle: Revisiting levodopa for advanced Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1063End Page: 1065Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00435-5Citation Count: 1
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial2022RESTRICTEDTitle: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1099End Page: 1109Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8Citation Count: 49
-
OPENTitle: Universal clinical Parkinson’s disease axes identify a major influence of neuroinflammationJournal Name: Genome MedicinePublisher: Springer Science and Business Media LLCVol: 14Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1186/s13073-022-01132-9Best OA location URL: https://genomemedicine.biomedcentral.com/counter/pdf/10.1186/s13073-022-01132-9Citation Count: 8
-
RESTRICTEDTitle: Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s DiseaseJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 36Issue #: 12Start Page: 1249End Page: 1267Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s40263-022-00973-7Citation Count: 5